Q2 Holdings, Inc. (NYSE:QTWO) shares increased 0.10% in last trading session and ended the day at $20.02. QTWO Gross Margin is 45.70% and its has a return on assets of -13.40%. Q2 Holdings, Inc. (NYSE:QTWO) quarterly performance is -25.07%.
On 10 February, Q2 Holdings, Inc. (NYSE:QTWO) reported a loss of $8.4 million in its fourth quarter. The Austin, Texas-based company said it had a loss of 22 cents per share. Losses, adjusted for stock option expense and costs related to mergers and acquisitions, were 9 cents per share.
ESCO Technologies Inc. (NYSE:ESE) ended the last trading day at $35.27. Company weekly volatility is calculated as 2.20% and price to cash ratio as 22.88. ESCO Technologies Inc. (NYSE:ESE) showed a weekly performance of 4.07%.
Canaccord Genuity reiterated their hold rating on shares of ESCO Technologies Inc. (NYSE:ESE) in a research report released on Wednesday, MarketBeat reports. They currently have a $37.00 price target on the stock.
On 19 February, Monster Worldwide, Inc. (NYSE:MWW) shares increased 1.40% and was closed at $2.90. MWW EPS growth in last 5 year was 23.20%. Monster Worldwide, Inc. (NYSE:MWW) year to date (YTD) performance is -49.39%.
On 11 February, Monster Worldwide, Inc. (NYSE:MWW) reported financial results for the fourth quarter and full year ended December 31, 2015. Revenue from continuing operations of $159.2 million decreased 6% at constant currency and 9% at actual rates compared to last year’s fourth quarter. Revenue from the Company’s Careers – North America operations decreased 8% year over year to $112.1 million.
Nivalis Therapeutics, Inc. (NASDAQ:NVLS) shares moved down -0.84% in last trading session and ended the day at $4.75. NVLS has a return on assets of -31.70%. Nivalis Therapeutics, Inc. (NASDAQ:NVLS) quarterly performance is -40.70%.
Nivalis Therapeutics, Inc. (NASDAQ:NVLS) announced the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for the Company’s lead investigational drug, N91115, a novel stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
Sientra, Inc. (NASDAQ:SIEN) caters to the Healthcare space. It has a net profit margin of -33.30% and weekly performance is -11.78%. On the last day of trading company shares ended up at $7.04. Sientra, Inc. (NASDAQ:SIEN) distance from 50-day simple moving average (SMA50) is -43.13%.
Sientra, Inc. (NASDAQ:SIEN) said it will resume selling all of its medical devices in the U.S. market from March 1, four months after it suspended sales of its breast implant devices to ensure technical compliance.
Leave a Reply